Medical device company Aethlon enters into clinical trial agreement with the UoC, Irvine

Friday, April 17, 2015

The clinical study will provide data to help direct future clinical investigations of the Aethlon Hemopurifier as a therapeutic candidate.

Aethlon Medical Inc., a medical device company developing therapies for infectious diseases and cancer, announced that it has entered into a clinical trial agreement with the University of California, Irvine.

The clinical study will provide data to help direct future clinical investigations of the Aethlon Hemopurifier as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes,which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis.

The study will seek to enroll five individuals with certain defined tumor types for a total study population of up to 45 subjects.

The tumor types include breast adenocarcinoma; colorectal, gastric and gastroesophageal; pancreatic, cholangiocarcinoma and lung; head and neck; melanoma; and ovarian adenocarcinoma.

 

 

nbcsandiego.com